Evidence map›Paper›PMID 20224751›Full record

ArticleViruses2009

Simultaneous Detection of CDC Category "A" DNA and RNA Bioterrorism Agents by Use of Multiplex PCR & RT-PCR Enzyme Hybridization Assays.

Jie He, Andrea J Kraft, Jiang Fan, Meredith Van Dyke, Lihua Wang, Michael E Bose, Marilyn Khanna, Jacob A Metallo, Kelly J Henrickson

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Laboratory Diagnosis of Lassa Fever.Journal of clinical microbiology · 2017
    Review
  9. Article
  10. Article
  11. Viral Hemorrhagic Fever Diagnostics.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Review
  12. Article
  13. Ebola virus disease in nonendemic countries.Journal of the Formosan Medical Association = Taiwan yi zhi · 2015
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jie HeDepartment of Pediatric, Medical College of Wisconsin, Milwaukee, WI 53226, USA; jhe@mcw.edu (J.H.); akraft@mcw.edu (A.J.K.); jfan@mcw.edu (J.F.); mvandyke@mcw.edu (M.V.D.); lwang@mcw.edu (L.W.); mbose@mcw.edu (M.E.B.); jmetallo@mcw.edu (J.A.M.).
Andrea J Kraft
Jiang Fan
Meredith Van Dyke
Lihua Wang
Michael E Bose
Marilyn Khanna
Jacob A Metallo
Kelly J Henrickson
Medical College of Wisconsin · USChildren's Hospital of Wisconsin · USNational Institutes of Health · US

Funding

Diagnostics for Sepsis and Community-Acquired PneumoniaU01AI066584 · NIAID · NEXOGEN, INC. · PI MATHER, PH.D., ELIZABETH L · 2005 to 2009
$2.4M
Multiplex PCR Detection of CDC 'A'Bioterrorism AgentsU01AI054374 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI HENRICKSON, KELLY J. · 2003 to 2005
$1.3M
NIAID NIH HHS U01 AI054374NIAID NIH HHS U01 AI066584
6 · The paper itself

Abstract

Assays to simultaneously detect multiple potential agents of bioterrorism are limited. Two multiplex PCR and RT-PCR enzyme hybridization assays (mPCR-EHA, mRT-PCR-EHA) were developed to simultaneously detect many of the CDC category "A" bioterrorism agents. The "Bio T" DNA assay was developed to detect: Variola major (VM), Bacillus anthracis (BA), Yersinia pestis (YP), Francisella tularensis (FT) and Varicella zoster virus (VZV). The "Bio T" RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1-4). Sensitivity and specificity of the 2 assays were tested by using genomic DNA, recombinant plasmid positive controls, RNA transcripts controls, surrogate (spiked) clinical samples and common respiratory pathogens. The analytical sensitivity (limit of detection (LOD)) of the DNA asssay for genomic DNA was 1x10(0)~1x10(2) copies/mL for BA, FT and YP. The LOD for VZV whole organism was 1x10(-2) TCID(50)/mL. The LOD for recombinant controls ranged from 1x10(2)~1x10(3)copies/mL for BA, FT, YP and VM. The RNA assay demonstrated LOD for RNA transcript controls of 1x10(4)~1x10(6) copies/mL without extraction and 1x10(5)~1x10(6) copies/mL with extraction for Ebola, RVF, Lassa and HSN. The LOD for dengue whole organisms was ~1x10(-4) dilution for dengue 1 and 2, 1x10(4) LD(50)/mL and 1x10(2) LD(50)/mL for dengue 3 and 4. The LOD without extraction for recombinant plasmid DNA controls was ~1x10(3) copies/mL (1.5 input copies/reaction) for Ebola, RVF, Lassa and HSN. No cross-reactivity of primers and probes used in both assays was detected with common respiratory pathogens or between targeted analytes. Clinical sensitivity was estimated using 264 surrogate clinical samples tested with the BioT DNA assay and 549 samples tested with the BioT RNA assay. The clinical specificity is 99.6% and 99.8% for BioT DNA assay and BioT RNA assay, respectively. The surrogate sensitivities of these two assays were 100% (95%CI 83-100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75-100) for BA (pX01) and dengue 1 using spiked clinical specimens. The specificity of both BioT multiplex assays on spiked specimens was 100% (95% CI 99-100). Compared to other available assays (culture, serology, PCR, etc.) both the BioT DNA mPCR-EHA and BioT RNA mRT-PCR-EHA are rapid, sensitive and specific assays for detecting many category "A" Bioterrorism agents using a standard thermocycler.

Identifiers

PMID20224751
PMCPMC2836126
OpenAlexW2000634530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.